Yahoo Web Search

Search results

1. • ...Bristol Myers Squibb’s Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle...

     Morningstar· 6 days ago

     U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma In ...

2. • 

     New Guide Tackles Best Practices For Making Allogeneic Cell Therapies

     BioresearchOnline· 2 days ago

     A comparatively thin body of GMP guidance supports a growing number of allogeneic cell therapies...

3. • 

     Cincinnati Children’s to boost trials capacity with new cell therapy centre

     Clinical Trials Arena via Yahoo Finance· 6 days ago

     Cincinnati Children's Hospital Medical Center in the US has announced plans to expand its clinical...

4. • Poseida Therapeutics Announces Virtual 2024 Annual Meeting of Stockholders

     Tehachapi News· 2 days ago

     Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments ...

5. • 

     Celularity reports advances in cancer T-cell therapy By Investing.com

     Investing.com· 2 days ago

     Celularity Inc. (NASDAQ: CELU), a biotechnology firm specializing in regenerative medicine,...

6. • 

     Chinese cell therapy may treat asthma long term with a single jab: study

     South China Morning Post· 3 days ago

     In their latest study, Peng’s team developed a new way to target this group of cytokines...

7. • New 'armored' CAR produces responses in patients whose cancers don't respond to current CAR T cell...

     Medical Xpress· 4 days ago

     A new "armored" form of CAR T cell therapy, developed by Carl June, MD, the Richard W. Vague Professor in Immunotherapy in the Perelman School of Medicine ...

8. • ASCO: New ‘Armored’ CAR produces significant r | Newswise

     Newswise· 6 days ago

     CHICAGO – While CAR T cell therapy has revolutionized treatment for many blood cancers, including non-Hodgkin lymphoma (NHL), many patients who receive ...

9. • Small Business - Cordele Dispatch | Cordele Dispatch

     Cordele Dispatch· 9 hours ago

     NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer

10. • 

      Galapagos selects Adaptimmune T-cell therapy for $665M biobucks collab

      FierceBiotech· 5 days ago

      Adaptimmune was facing a financing cliff until Galapagos walked in with a sprawling licensing deal...